Detalhe da pesquisa
1.
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Thromb Haemost
; 124(3): 263-273, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224883
2.
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC-2 Study.
JACC Cardiovasc Interv
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38597172
3.
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
JACC Cardiovasc Interv
; 16(1): 36-46, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36317958
4.
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
JACC Cardiovasc Interv
; 16(20): 2528-2539, 2023 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37609698
5.
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC Cardiovasc Interv
; 14(21): 2410-2412, 2021 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34736741